0H8T Stock Chart & Stats
$5.98
$0.21(4.13%)
At close: 4:00 PM EDT
$5.98
$0.21(4.13%)
Day’s Range― - ―
52-Week Range$2.11 - $6.58
Previous CloseN/A
Volume504.00
Average Volume (3M)5.17K
Market Cap
$557.88M
Enterprise Value$665.37M
Total Cash (Recent Filing)$91.56M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Nov 11, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.58
Shares Outstanding147,198,900
10 Day Avg. Volume3,225
30 Day Avg. Volume5,166
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)3.58
Price to Sales (P/S)47.18
P/FCF Ratio-7.84
Enterprise Value/Market Cap1.19
Enterprise Value/Revenue80.96
Enterprise Value/Gross Profit84.67
Enterprise Value/Ebitda-8.83
Forecast
1Y Price Target
$12.00Price Target Upside100.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.65
Revenue Forecast (FY)$6.18M
Bulls Say, Bears Say
Bulls Say
ATI-052 Clinical ValidationPositive Phase 1b proof-of-concept results provide clinical validation for ATI-052 across atopic dermatitis and asthma, including rapid responses and favorable tolerability. This supports advancing the program into later-stage development and strengthens the pipeline’s potential strategic value.
Liquidity PositionReported liquidity of about $204.6 million gives Aclaris resources to advance ATI-052 and its broader immuno-inflammatory pipeline. This financial cushion can support planned clinical work over the coming quarters and reduce immediate dependence on additional financing.
Low Financial LeverageMinimal debt and positive equity provide financial flexibility compared with a heavily leveraged development-stage biotechnology company. The absence of substantial debt service obligations leaves more available capital for research, clinical execution, and portfolio prioritization.
Bears Say
Contracting RevenueA shrinking revenue base limits internally generated funding and indicates that collaboration-related income has not established a durable growth trajectory. With product sales not yet central to the model, continued contraction increases reliance on pipeline progress and external capital.
Persistent Cash BurnMaterial ongoing cash burn consumes liquidity while Aclaris funds research and clinical development, and the company remains dependent on its cash balance or future financing. Continued negative free cash flow can constrain the pace and breadth of pipeline investment.
Equity Dilution RiskThe underwritten equity offering provides funding but expands the potential share count through common stock and pre-funded warrants. Repeated reliance on equity capital can dilute existing holders and reflects the company’s need to finance operations before commercial cash generation.
Aclaris Therapeutics News
0H8T FAQ
What was Aclaris Therapeutics’s price range in the past 12 months?
Aclaris Therapeutics lowest share price was $2.11 and its highest was $6.58 in the past 12 months.
What is Aclaris Therapeutics’s market cap?
Aclaris Therapeutics’s market cap is $557.88M.
When is Aclaris Therapeutics’s upcoming earnings report date?
Aclaris Therapeutics’s upcoming earnings report date is Nov 11, 2026 which is in 14 days.
How were Aclaris Therapeutics’s earnings last quarter?
Aclaris Therapeutics released its earnings results on Aug 06, 2026. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.16 by $0.01.
Is Aclaris Therapeutics overvalued?
According to Wall Street analysts Aclaris Therapeutics’s price is currently Undervalued.
Does Aclaris Therapeutics pay dividends?
Aclaris Therapeutics does not currently pay dividends.
What is Aclaris Therapeutics’s EPS estimate?
Aclaris Therapeutics’s EPS estimate is -0.16.
How many shares outstanding does Aclaris Therapeutics have?
Aclaris Therapeutics has 147,198,900 shares outstanding.
What happened to Aclaris Therapeutics’s price movement after its last earnings report?
Aclaris Therapeutics reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.16. Following the earnings report the stock price went down -4.688%.
Which hedge fund is a major shareholder of Aclaris Therapeutics?
Currently, no hedge funds are holding shares in GB:0H8T
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aclaris Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.00 (100.67% Upside)
$12.00 (100.67% Upside)
Blogger Sentiment
Neutral
GB:0H8T Sentiment 67%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
76.27%
12-Months-Change
Fundamentals
Return on Equity
-61.65%
Trailing 12-Months
Asset Growth
-5.00%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Aclaris Therapeutics
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.
0H8T Stock 12 Month Forecast
Average Price Target
$12.00
▲(100.67% Upside)